PAPER Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE
SEARCH RESULTS
331254 RESULTS
PAPER de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ
Visualizing vesicular dopamine dynamics in Parkinson's disease.
Synapse. 2009 Aug;63(8):713-6. PubMed: 19391152Muscle-Boosting Therapy Fails in Phase 2 Trial for ALS
RESEARCH NEWS 2014-04-26 Research News The experimental muscle-stimulating drug Tirasemtiv was unable to improve amyotrophic lateral sclerosis (ALS) symptoms in a Phase 2 clinical trial, according to top-line data. Announced April 25 by the drug’s developer, South San Francisco-b
PAPER Shefner JM, Watson ML, Meng L, Wolff AA, Neals/Cytokinetics STUDY Team
A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis.
Amyotroph Lateral Scler Frontotemporal Degener. 2013 Dec;14(7-8):574-81. Epub 2013 Aug 19 PubMed: 23952636PAPER Winblad B, Kivipelto M, Andersen P, Johansson G, Andreasen N
[Treatment of early stages of Alzheimer's disease: New guidelines are in the pipeline].
Lakartidningen. 2013 Sep 11-17;110(37):1613. PubMed: 24163935PAPER Brown LA, Jin J, Ferrell D, Sadic E, Obregon D, Smith AJ, Tan J, Giunta B
Efavirenz promotes β-secretase expression and increased Aβ1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND).
PLoS One. 2014;9(4):e95500. Epub 2014 Apr 23 PubMed: 24759994PAPER Liu MX, Liu JG, Li H
[Chinese materia medica monomers and components research progress on treating Alzheimer's disease by targeting gamma-secretase].
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014 Mar;34(3):376-9. PubMed: 24758094PAPER Jung Y, Dickson DW, Murray ME, Whitwell JL, Knopman DS, Boeve BF, Jack CR Jr, Parisi JE, Petersen RC, Josephs KA
TDP-43 in Alzheimer's disease is not associated with clinical FTLD or Parkinsonism.
J Neurol. 2014 Jul;261(7):1344-8. Epub 2014 Apr 24 PubMed: 24760339PAPER Woodling NS, Wang Q, Priyam PG, Larkin P, Shi J, Johansson JU, Zagol-Ikapitte I, Boutaud O, Andreasson KI
Suppression of Alzheimer-associated inflammation by microglial prostaglandin-E2 EP4 receptor signaling.
J Neurosci. 2014 Apr 23;34(17):5882-94. PubMed: 24760848PAPER Parra-Damas A, Valero J, Chen M, España J, Martín E, Ferrer I, Rodríguez-Alvarez J, Saura CA
Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages.
J Neurosci. 2014 Apr 23;34(17):5776-87. PubMed: 24760838PAPER Guo Y, Zhang Z, Zhou B, Wang P, Yao H, Yuan M, An N, Dai H, Wang L, Zhang X, Liu Y
Grey-matter volume as a potential feature for the classification of Alzheimer's disease and mild cognitive impairment: an exploratory study.
Neurosci Bull. 2014 Jun;30(3):477-89. Epub 2014 Apr 23 PubMed: 24760581PAPER Neumann B, Yarman A, Wollenberger U, Scheller F
Characterization of the enhanced peroxidatic activity of amyloid β peptide-hemin complexes towards neurotransmitters.
Anal Bioanal Chem. 2014 May;406(14):3359-64. Epub 2014 Apr 24 PubMed: 24760399PAPER Relkin N
Clinical trials of intravenous immunoglobulin for Alzheimer's disease.
J Clin Immunol. 2014 Jul;34 Suppl 1:S74-9. Epub 2014 Apr 24 PubMed: 24760112PAPER Counts SE, Ray B, Mufson EJ, Perez SE, He B, Lahiri DK
Intravenous immunoglobulin (IVIG) treatment exerts antioxidant and neuropreservatory effects in preclinical models of Alzheimer's disease.
J Clin Immunol. 2014 Jul;34 Suppl 1:S80-5. Epub 2014 Apr 24 PubMed: 24760109PAPER Verdan C, Casarsa D, Perrout MR, Santos M, Alves de Souza J, Nascimento O, Freire Coutinho ES, Laks J
Lower mortality rate in people with dementia is associated with better cognitive and functional performance in an outpatient cohort.
Arq Neuropsiquiatr. 2014 Apr;72(4):278-82. PubMed: 24760091Current Filters
No filters selected